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Supplemental Methods
Blood sampling, platelet phenotyping and DNA isolation
Venous blood was drawn from each patient into commercial 7.5% K3 EDTA tubes (for complete blood count [CBC] , and DNA isolation), and into buffered 3.2% sodium citrate for platelet studies. Platelet function testing was performed mainly in citrated plateletrich-plasma. Assays included, as appropriate, blood smears, PFA-100, light transmission aggregometry, flow cytometric evaluation of platelet glycoprotein's and agonist-induced platelet activation, alpha and dense granule secretion, clot retraction, immunoblotting analysis of selected proteins, immunofluorescence and electron microscopy. 1-3 Genomic DNA from peripheral blood samples was isolated using a DNeasy blood and tissue kit, following the manufacturer's protocol (Qiagen, Hilden, Germany). DNA concentration was measured using a Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA).
High-throughput sequencing (HTS)
The HTS test was performed on a MiSeq Instrument, running MiSeq Control Software and applying a Nextera sequencing design (Illumina). Fifty ng of patient´s DNA was sequenced following Illumina's standardized protocol. DNA libraries were normalized to 4 nM and pooled in equal volumes. We used the 300-cycle reagent kit. Specifically, samples were sequenced using paired 150 nt reads, multiplexing twelve, dual-indexed samples per run.
Twenty-four samples were included in each run.
Sanger sequencing
To verify candidate variants found using the HTS multigenic platform and to examine their segregation among available family members, we performed standard Sanger sequencing. Briefly, specific forward and reverse primers were designed using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) (sequences available on request). Genomic DNA was amplified with the Fast Start High Fidelity PCR System (Roche, Basel, Switzerland) following the manufacturer's instructions, with some variations in the annealing temperature. DNA sequences were evaluated using Chromas Lite v2.1.1 (Technelysium, South Brisbane, Australia) and DS Gene v1.5 (Accerlys, San Diego, CA) software. Data were analyzed using annotations of genome version hg19/GRCh37. 
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Legend. In each patient the filtering procedure described in Methods, led to calling one o more gene variants. These variants were qualified for contribution to the patient disease using a color code: i) Red: main candidate causal variants, which were classified for pathogenicity according to ACMG guidelines 4 ; Yellow: variants in other genes that could fit with the patient phenotype (for instance, gene already know to be involved in inherited thrombocytopenia; Green: variants in other genes unknown to be involved in phenotype similar with that displayed by the patient. 
